931-49-7C#CC1=CCCCC1DKFHWNGVMWFBJE-UHFFFAOYSA-Nstructure in first source
931-49-7DTXSID5073244CHEMBL232741Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Warning
H226 (100%): Flammable liquid and vapor [Warning Flammable liquids]
P210, P233, P240, P241, P242, P243, P261, P264, P264+P265, P271, P280, P302+P352, P303+P361+P353, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P370+P378, P403+P233, P403+P235, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Chemical: Cyclohexene, 1-ethynyl-
Cyclohexene, 1-ethynyl-: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Uses1-ETHYNYLCYCLOHEXENE can be used to prepare 4-phenoxyquinoline-N-sulfonylamidine compounds with the following structure. These compounds can act as tyrosine kinase inhibitors, especially c-Met inhibitors. c-Met is highly expressed in most solid tumors and some sarcomas and is closely associated with poor prognosis, such as lung cancer, breast cancer, colon cancer, prostate cancer, liver cancer, gastric cancer, and glioma. Furthermore, patients with high HGF/c-Met expression levels have stronger resistance to chemotherapy and radiotherapy. Besides abnormal HGF/c-Met expression, c-Met can also be activated in cancer patients through gene mutation and gene amplification.